IL6 and central nervous system cancer: A recent meta-analysis proposed that circulating interleukin 6 (IL-6) and C-Reactive Protein (CRP) could potentially serve as robust biomarkers for predicting poor prognosis in patients with glioma (Feng et al., 2019).